Achillion to Report Fourth Quarter and Year End 2012 Financial Results and Host Conference Call on February 20, 2013

Tue Feb 19, 2013 4:05pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130219:nGNXUXEVIa

NEW HAVEN, Conn., Feb. 19, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)
today announced that it plans to release fourth quarter and year-end 2012 financial results on
Wednesday, February 20, 2013, after the market closes. Achillion will also host a conference call
and live webcast to discuss these financial results and to provide an update on the Company's
hepatitis C (HCV) development programs that afternoon at 5:00 p.m. EST.

To participate in the conference call, please dial (877) 266-0482 in the U.S. or (631) 291-4567
for international callers. A live audio webcast of the call will be accessible at
www.achillion.com
http://www.globenewswire.com/newsroom/ctr?d=10022281&l=2&a=www.achillion.com&u=http%3A%2F%2Fwww.achillion.com
, under the News Center section of the website. Please connect to Achillion's website several
minutes prior to the start of the broadcast to ensure adequate time for any software download that
may be necessary.

A replay of the webcast will be available on www.achillion.com
http://www.globenewswire.com/newsroom/ctr?d=10022281&l=3&a=www.achillion.com&u=http%3A%2F%2Fwww.achillion.com
. Alternatively, a replay of the conference call can be accessed beginning at approximately 8:00
p.m. EST on February 20, 2013, through 11:59 p.m. ET on February 27, 2013 by dialing (855)
859-2056 or (404) 537-3406 for international callers. The replay passcode is 13062862.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments
to patients with infectious disease. Achillion's proven discovery and development teams have
advanced multiple product candidates with novel mechanisms of action. Achillion is focused on
solutions for the most challenging problems in infectious disease including hepatitis C and
resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit
www.achillion.com
http://www.globenewswire.com/newsroom/ctr?d=10022281&l=5&a=www.achillion.com&u=http%3A%2F%2Fwww.achillion.com
 or call 1-203-624-7000.

CONTACT: Company Contact:
         Glenn Schulman
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         gschulman@achillion.com
         
         Media:
         Christin Culotta Miller
         Ogilvy PR
         Tel. (646) 229-5178
         christin.miller@ogilvypr.com
         
         Investors:
         Mary Kay Fenton
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         mfenton@achillion.com
         
         Investors:
         Seth Lewis
         The Trout Group, LLC
         Tel. (646) 378-2952
         slewis@troutgroup.com